All In Biotech

Drug Trial Radar · NCT02561793

DHEA Versus Placebo in Women With Poor Ovarian Response

Does DHEA Improve Pregnancy Rate in Women Undergoing IVF/Intracytoplasmatic Sperm Injection(ICSI) With Expected Poor Ovarian Response According to the Bologna Criteria? A Double Blind Randomized Placebo Controlled Study

Last checked: Nov 20, 2026Latest source record: Jul 6, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

440

Planned (sponsor's estimate)

Start

Oct 2015

Primary completion

Sep 2017

Study completion Sep 2017

Sponsor

Lead sponsor
Cairo UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 28, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 20 years, up to 43 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

440 women with expected poor ovarian response undergoing IVF/ICSI (intracytoplasmic sperm injection) will be randomly divided into 2 groups using computer generated random numbers . Group 1 ( study group) will receive Dehydroepiandrosterone (DHEA) 25 mg ( DHEA 25mg, Natrol , USA) t.d.s daily for 12 weeks before starting IVF/ICSI cycle. Group 2 ( control group) will receive a placebo. Patients included in the study will be subjected to full history taking and clinical examination. On the second day of menstruation serum FSH, LH, Prolactin and Oestradiol will be assessed and the antral follicular count (AFC) will be assessed using a vaginal ultrasound scan. AFC will be defined as the number of follicles measuring 3-10mm. All patients will have gonadotropin antagonist protocol with Human menopausal gonadotrophin (HMG) stimulation until the day of (Human chorionic gonadotrophin (HCG) administration. On the day of HCG administration, ovarian ultrasound scan will be performed using a transvaginal probe. Oocytes will be aspirated 34-36 hours after HCG administration. Oocytes will be fertilized and embryos will be transferred. Both groups will be compared regarding the proportion of pregnancy.

Conditions

  • Subfertility

Interventions

  • DHEADrug

    Women will receive DHEA 12 weeks before starting IVF/ICSI

  • PlaceboDrug

    women will receive a placebo 12 weeks before starting IVF/ICSI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ongoing pregnancy rateTime frame: 12 weeks after embryo transfer

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cairo University Hospitals

    Cairo, Egypt · Recruiting

  • Dar AlTeb subfertility centre

    Giza, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.